Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Deferred Tax Liability: 2016-2019

Historic Non-Current Deferred Tax Liability for Niagen Bioscience (NAGE) over the last 4 years, with Dec 2019 value amounting to $218,000.

  • Niagen Bioscience's Non-Current Deferred Tax Liability rose 59.12% to $218,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $218,000, marking a year-over-year increase of 59.12%. This contributed to the annual value of $218,000 for FY2019, which is 59.12% up from last year.
  • According to the latest figures from FY2019, Niagen Bioscience's Non-Current Deferred Tax Liability is $218,000, which was up 59.12% from $137,000 recorded in FY2018.
  • Niagen Bioscience's Non-Current Deferred Tax Liability's 5-year high stood at $413,000 during FY2016, with a 5-year trough of $137,000 in FY2018.
  • For the 3-year period, Niagen Bioscience's Non-Current Deferred Tax Liability averaged around $166,333, with its median value being $144,000 (2017).
  • Per our database at Business Quant, Niagen Bioscience's Non-Current Deferred Tax Liability tumbled by 63.91% in 2017 and then skyrocketed by 59.12% in 2019.
  • Yearly analysis of 4 years shows Niagen Bioscience's Non-Current Deferred Tax Liability stood at $413,000 in 2016, then decreased by 3.39% to $399,000 in 2016, then slumped by 63.91% to $144,000 in 2017, then fell by 4.86% to $137,000 in 2018, then skyrocketed by 59.12% to $218,000 in 2019.